section name header

Pronunciation ⬇

soo-KRAL-fate

Classifications ⬆ ⬇

Therapeutic Classification: antiulcer agents

Pharmacologic Classification: gi protectants

Indications ⬆ ⬇

REMS

Unlabeled Use:
  • Management of gastric ulcer or gastroesophageal reflux.
  • Prevention of gastric mucosal injury caused by high-dose aspirin or other NSAIDs in patients with rheumatoid arthritis or in high-stress situations (e.g., intensive care unit). Suspension: Mucositis/stomatitis/rectal or oral ulcerations from various etiologies.

Action ⬆ ⬇

  • Aluminum salt of sulfated sucrose reacts with gastric acid to form a thick paste, which selectively adheres to the ulcer surface.
Therapeutic effects:
  • Protection of ulcers, with subsequent healing.

Pharmacokinetics ⬆ ⬇

Absorption: Systemic absorption is minimal (<5%).

Distribution: Unknown.

Metabolism/Excretion: >90% is eliminated in the feces.

Half-Life: 6–20 hr.

Time/Action Profile ⬆ ⬇

(mucosal protectant effect)

ROUTEONSETPEAKDURATION
PO1–2 hrunknown6 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: pruritus, rash

Endo: hyperglycemia (with suspension)

GI: constipation, diarrhea, dry mouth, gastric discomfort, indigestion, nausea

Neuro: dizziness, drowsiness

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Treatment of Ulcers

Gastroesophageal Reflux

Stomatitis

Proctitis

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Carafate

Canadian Brand Names ⬆ ⬇

Cytogard, Sulcrate, Sulcrate Plus

Code ⬆

NDC Code